FP40-1 Prevalence of benign and malignant secondary neoplasms in patients with primary aldosteronism

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: FP40-Renin-Angiotensin-Aldosterone System/Endocrine Hypertension
Basic/Translational
Monday, June 17, 2013: 10:45 AM-11:15 AM
Presentation Start Time: 10:45 AM
Room 135 (Moscone Center)

Poster Board MON-726
Katharina Lang*1, Katrin Weber1, Marcus Quinkler2, Anna Pallauf3, Henri Wallaschofski4, Anke Hannemann4, Oliver Vonend5, Holger Willenberg5, Martin Reincke3, Bruno Allolio1 and Stefanie Hahner1
1University of Wuerzburg, Germany, 2Charité University Medicine Berlin, Campus Mitte, Berlin, Germany, 3University of Munich, Munich, Germany, 4University Medicine Greifswald, Greifswald, Germany, 5University Hospital Duesseldorf, Duesseldorf, Germany
Context: Primary aldosteronism (PA) is the most common cause of secondary hypertension. In vitro, aldosterone excess can cause oxidative stress leading to DNA damage. Single case reports describe a coincidence of PA with renal cell carcinoma and other tumors. However, no data on the prevalence of benign and malignant neoplasms in patients with PA exists. Methods: In the multicentre MEPHISTO study the prevalence of benign and malignant tumors was investigated in 338 patients with confirmed PA both retro- and prospectively. The SHIP cohort of hypertensive individuals served as a matched control group. Results: Of the 338 patients (199 male and 139 female) 120 (35.5%) had been diagnosed with a tumor at any time of their life, 31 had more than one tumor diagnosis. In total, 159 neoplasms were identified which were in 62% of benign and in 25% of malignant dignity (13% unknown dignity). 38% (n=37) of all benign secondary neoplasms were derived from endocrine tissue (thyroid, parathyroid and pituitary). The remaining benign neoplasms were located in skin (6%), prostate (21%), female reproductive organs (10%), lung, and brain or were characterized as lipoma, hemangioma and tumor of the sebaceous glands (together 13%). By contrast, only 8% (n=3) of the malignant tumors were of endocrine origin (all thyroid carcinomas). Most of the malignant tumors were skin tumors (21%). Renal cell carcinoma was diagnosed in 5 patients (13%), prostate cancer in 6 patients (15%). Less frequently diagnosed were malignant tumors in gastrointestinal tract (8%), leukemia, breast cancer and malignant tumors in lung, larynx, reproductive organs or brain (together 33%). Conclusion: In this cohort of PA patients a very high prevalence of benign endocrine neoplasms was found. Interestingly, a relatively high prevalence of renal cell carcinoma (13% of malignant neoplasms) was further observed. Renal cell carcinoma generally accounts for only 3.3-4.4% of all malignant tumors in Germany. Probable pathophysiological backgrounds are subject of ongoing studies.

Nothing to Disclose: KL, KW, MQ, AP, HW, AH, OV, HW, MR, BA, SH

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm

Previous Abstract | Next Abstract >>